FDA Authorizes New IND to Evaluate Impact of Multi-Strain Probiotic DS-01^TMon Gut Microbiota of Patients with IBS

The regulatory acceptance enables a team of gastroenterologists at Beth Israel Deaconess Medical Center to initiate a Phase II randomized, triple-blind, and placebo-controlled clinical trial to investigate the role of the gut microbiome in patients with Irritable Bowel Syndrome, as well as the impact of DS-01™ on both intestinal cells and metabolic output of the native intestinal microbial communities.